Sectors
ASND
Ascendis Pharma A/S
229.25
1 x 228.21
1 x 229.46
bid
ask
+
1.01
0.44%
1 @ 04:00 PM
229.25 +0.00 (0.00%)
Ytd 7.51%
1y 50.67%
223.83
day range
229.50
137.41
52 week range
242.09
Open 226.58 Prev Close 228.24 Low 223.83 High 229.50 Mkt Cap 14.07B
Vol 736.00K Avg Vol 678.66K EPS -4.36 P/E N/A Forward P/E 17.84
Beta 0.48 Short Ratio 5.21 Inst. Own 107.37% Dividend N/A Div Yield N/A
Ex Div Date N/A Earning 04-30 50-d Avg 227.54 200-d Avg 204.27 1yr Est 288.81
Earning
Date For Estimate Reported Surprise surprise %
2026-05-07 2026-03 0.33 N/A N/A N/A
2026-02-11 2025-12 0 N/A -0.58 -966.67%
2025-11-12 2025-09 0 N/A -0.76 -185.37%
2025-08-07 2025-06 0 N/A 0.49 34.51%
2025-05-01 2025-03 0 N/A -0.1 -6.41%
2025-02-12 2024-12 0 N/A 0.52 43.33%
Upgrade / Downgrade
Date Firm Action From To
2026-03-03 RBC Capital Upgrade Outperform Outperform
2026-02-12 Oppenheimer Upgrade Outperform Outperform
2026-02-12 Wedbush Upgrade Outperform Outperform
2026-01-30 B of A Securities Upgrade Buy Buy
2026-01-28 Barclays Upgrade Overweight
2026-01-20 RBC Capital Upgrade Outperform Outperform
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 RA Capital Management, L.P. 10.28M 2.36B 16.50%
2025-12-30 Westfield Capital Management Co LP 5.19M 1.19B 8.32%
2025-12-30 Avoro Capital Advisors LLC 5.11M 1.17B 8.20%
2025-12-30 FMR, LLC 4.15M 952.15M 6.66%
2025-12-30 Janus Henderson Group PLC 4.06M 931.13M 6.52%
2025-12-30 Artisan Partners Limited Partnership 3.23M 739.53M 5.18%
Fund Ownership
Report Date Organization Position Value Percentage
2025-11-29 MFS Series Trust IV-MFS Mid Cap Growth Fund 1.28M 293.38M 2.05%
2025-12-30 GROWTH FUND OF AMERICA 1.21M 277.32M 1.94%
2026-01-30 VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund 1.10M 252.97M 1.77%
2025-12-30 Franklin Custodian Funds-FRANKLIN DYNATECH FUND 1000.00K 229.25M 1.60%
2025-12-30 T. Rowe Price Mid-Cap Growth Fund, Inc. 784.10K 179.75M 1.26%
2025-12-30 JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund 731.87K 167.78M 1.17%